BC Week In Review | Jun 23, 2014
Company News

Maxygen Inc other news

Maxygen’s board approved a second and final liquidating distribution of $0.09 per share, to be paid on or about June 30. Shareholders received an initial payout of $69.5 million, or about $2.50 per share, after...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BC Week In Review | Sep 2, 2013
Company News

Maxygen hematology, other news

Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen said it could...
BC Week In Review | Jun 17, 2013
Company News

Maxygen hematology, other news

Maxygen said its board approved a plan to liquidate and dissolve the company. The estimated shareholder payout is about $68.2-$69.6 million, or about $2.45-$2.50 per share based on 27.8 million shares outstanding as of May...
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
BC Week In Review | Apr 15, 2013
Company News

Maxygen management update

Maxygen Inc., Santa Clara, Calif.   Business: Enabling technology   Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president...
BC Week In Review | May 21, 2012
Company News

Maxygen, Bayer deal

Maxygen will receive a $30 million milestone payment from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's hemophilia program. The payment was triggered by undisclosed clinical development of...
BioCentury | May 21, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Osiris Therapeutics Inc. (NASDAQ:OSIR) gained $0.25 to $5.55 last week after Health Canada granted Prochymal conditional approval to treat acute graft-versus-host disease (GvHD) in children. Prochymal is an IV formulation of mesenchymal stem...
BC Week In Review | Jan 16, 2012
Financial News

Maxygen financial update

Maxygen said its board approved a share repurchase program for up to $10 million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc. (NASDAQ:MAXY), Redwood City, Calif.  ...
BC Week In Review | Nov 14, 2011
Company News

Maxygen other news

Maxygen said HHS's Biomedical Advanced Research and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen said BARDA found its proposal "technically sound" but raised concerns about the dependence...
Items per page:
1 - 10 of 290
BC Week In Review | Jun 23, 2014
Company News

Maxygen Inc other news

Maxygen’s board approved a second and final liquidating distribution of $0.09 per share, to be paid on or about June 30. Shareholders received an initial payout of $69.5 million, or about $2.50 per share, after...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BC Week In Review | Sep 2, 2013
Company News

Maxygen hematology, other news

Maxygen said its shareholders approved a plan previously approved by Maxygen's board to liquidate and dissolve the company. The initial shareholder payout is about $69.5 million, or about $2.50 per share. Maxygen said it could...
BC Week In Review | Jun 17, 2013
Company News

Maxygen hematology, other news

Maxygen said its board approved a plan to liquidate and dissolve the company. The estimated shareholder payout is about $68.2-$69.6 million, or about $2.45-$2.50 per share based on 27.8 million shares outstanding as of May...
BioCentury | Jun 17, 2013
Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
BC Week In Review | Apr 15, 2013
Company News

Maxygen management update

Maxygen Inc., Santa Clara, Calif.   Business: Enabling technology   Hired: Alejandro Zaffaroni, Ph.D., as CEO, currently a director at Affymax Research Institute (Palo Alto, Calif.); Russell Howard, Ph.D., as president and COO; formerly president...
BC Week In Review | May 21, 2012
Company News

Maxygen, Bayer deal

Maxygen will receive a $30 million milestone payment from Bayer's Bayer HealthCare LLC subsidiary under a 2008 deal in which the pharma acquired Maxygen's hemophilia program. The payment was triggered by undisclosed clinical development of...
BioCentury | May 21, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Osiris Therapeutics Inc. (NASDAQ:OSIR) gained $0.25 to $5.55 last week after Health Canada granted Prochymal conditional approval to treat acute graft-versus-host disease (GvHD) in children. Prochymal is an IV formulation of mesenchymal stem...
BC Week In Review | Jan 16, 2012
Financial News

Maxygen financial update

Maxygen said its board approved a share repurchase program for up to $10 million through Dec. 31. Maxygen, which closed Friday at $5.51, has 28.1 million shares outstanding. Maxygen Inc. (NASDAQ:MAXY), Redwood City, Calif.  ...
BC Week In Review | Nov 14, 2011
Company News

Maxygen other news

Maxygen said HHS's Biomedical Advanced Research and Development Authority (BARDA) rejected a proposal for MAXY-G34 to treat acute radiation syndrome (ARS). Maxygen said BARDA found its proposal "technically sound" but raised concerns about the dependence...
Items per page:
1 - 10 of 290